☆ 4.4 Editorial Material

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D

DIABETES THERAPY (2022)

Get Full Text
Add to Collection

Journal

DIABETES THERAPY
Volume 13, Issue SUPPL 1, Pages 1-3

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s13300-022-01281-5

Keywords

Type 2 diabetes; SGLT2 inhibitors; Cardiorenal; Cardiovascular disease; Kidney disease; Heart failure; Morbidity; Mortality; Chronic kidney disease; Cardiorenal continuum

Categories

Endocrinology & Metabolism

Funding

  1. AstraZeneca

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.